[go: up one dir, main page]

NO20082988L - Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer - Google Patents

Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer

Info

Publication number
NO20082988L
NO20082988L NO20082988A NO20082988A NO20082988L NO 20082988 L NO20082988 L NO 20082988L NO 20082988 A NO20082988 A NO 20082988A NO 20082988 A NO20082988 A NO 20082988A NO 20082988 L NO20082988 L NO 20082988L
Authority
NO
Norway
Prior art keywords
sustained release
polylactide
release formulation
formulation including
glycolide polymers
Prior art date
Application number
NO20082988A
Other languages
English (en)
Inventor
Markus Ahlheim
Holger Petersen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082988(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0526247A external-priority patent/GB0526247D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20082988L publication Critical patent/NO20082988L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Peptides Or Proteins (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

Det beskrives formuleringer for vedvarende frigivning omfattende, som aktiv bestanddel, oktreotid eller et farmasøytisk akseptabelt salt derav og to eller flere forskjellige polylaktid-ko-glykolidpolymerer, PLGA'er.
NO20082988A 2005-12-22 2008-07-02 Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer NO20082988L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526247A GB0526247D0 (en) 2005-12-22 2005-12-22 Organic compounds
EP06119086 2006-08-17
PCT/EP2006/012313 WO2007071395A1 (en) 2005-12-22 2006-12-20 Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers

Publications (1)

Publication Number Publication Date
NO20082988L true NO20082988L (no) 2008-08-29

Family

ID=37772904

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082988A NO20082988L (no) 2005-12-22 2008-07-02 Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer

Country Status (22)

Country Link
US (7) US20090004283A1 (no)
EP (3) EP1968549B1 (no)
JP (4) JP2009520727A (no)
KR (5) KR101458728B1 (no)
CN (1) CN103251929A (no)
AR (1) AR058591A1 (no)
AU (1) AU2006328950B2 (no)
BR (2) BR122019027412B8 (no)
CA (1) CA2631811C (no)
CL (1) CL2018003398A1 (no)
EC (1) ECSP088560A (no)
ES (2) ES2492641T3 (no)
IL (1) IL191842A0 (no)
IN (1) IN2015DN03936A (no)
MA (1) MA30064B1 (no)
NO (1) NO20082988L (no)
PE (1) PE20071139A1 (no)
PL (2) PL2359809T3 (no)
PT (2) PT1968549E (no)
RU (1) RU2464972C2 (no)
TW (2) TWI468172B (no)
WO (1) WO2007071395A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019284B1 (ru) † 2007-06-06 2014-02-28 Дебиофарм Рисёрч Энд Мэньюфэкчуринг Са Фармацевтическая композиция с пролонгированным высвобождением, приготовленная из микрочастиц
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
ES2324009B1 (es) * 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
WO2009095450A1 (en) * 2008-01-30 2009-08-06 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
ES2629131T3 (es) * 2008-09-17 2017-08-07 Chiasma Inc. Composiciones farmacéuticas y métodos de suministro relacionados.
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
AR074603A1 (es) * 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
EP2389161A2 (en) * 2009-01-23 2011-11-30 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
US20120022137A1 (en) * 2010-07-21 2012-01-26 Rivers Hongwen M METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
US20120156304A1 (en) * 2010-12-15 2012-06-21 Thomas Tice Branched polyol polyesters, blends, and pharmaceutical formulations comprising same
AU2012248038B2 (en) 2011-04-25 2015-11-12 Geneora Pharma (Shijiazhuang) Co., Ltd. Risperidone sustained release microsphere composition
CN102488619B (zh) * 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
WO2016084849A1 (ja) * 2014-11-25 2016-06-02 Cbc株式会社 ヤヌス微粒子及びその製造方法
DK3253401T3 (da) 2015-02-03 2025-05-19 Amryt Endo Inc Behandling af akromegali med oral octreotid
JP6165356B2 (ja) * 2015-06-26 2017-07-19 オリンパス株式会社 内視鏡システム
US12396951B2 (en) * 2016-12-27 2025-08-26 Upexmed Co. Ltd. Prevention of local tumor recurrence following surgery using sustainedand/or delayed release of medicaments contained in micro-particles
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
AU2020348947B2 (en) 2019-09-16 2025-11-27 Amgen Inc. Method for external sterilization of drug delivery device
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
US11617720B2 (en) 2020-05-08 2023-04-04 M. Technique Co., Ltd. Main agent uniformly dispersed microsphere and a sustained release formulation comprising the same
EP4147720A4 (en) * 2020-05-08 2023-04-26 M. Technique Co., Ltd. MICROPHONES WITH A UNIFORMLY DISPERSED BIOACTIVE SUBSTANCE AND PREPARATION WITH DELAYED RELEASE CONTAINING THEM
KR20220163416A (ko) 2020-05-08 2022-12-09 엠. 테크닉 가부시키가이샤 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE19375086I2 (de) 1979-11-27 2003-01-09 Novartis Ag Polypeptide Verfahren zu ihrer Herstellung pharmazeutische Zusammensetzungen die diese Polypeptide enthalten und ihre Verwendung
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
KR100260632B1 (ko) * 1992-12-28 2000-07-01 성재갑 이식형 소마토트로핀 조성물
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US6447796B1 (en) * 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6197350B1 (en) * 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
JP2002511075A (ja) * 1997-06-04 2002-04-09 デビオ ルシェルシュ ファルマスティク ソシエテ アノニム 薬学的活性成分の制御放出のためのインプラント及びその製造方法
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
ES2292655T3 (es) * 2002-03-15 2008-03-16 Alrise Biosystems Gmbh Microparticulas y procedimiento para su preparacion.
JP2006508127A (ja) * 2002-11-06 2006-03-09 アルザ・コーポレーション 制御された放出性デポー剤配合物
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
EP2462923A3 (en) * 2003-07-18 2012-08-29 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
WO2005009357A2 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
SI1786400T1 (sl) * 2004-08-12 2009-08-31 Quest Pharmaceutical Services Farmacevtski sestavki za dajanje biološko aktivnih spojin z nadzorovanim sproščanjem

Also Published As

Publication number Publication date
ECSP088560A (es) 2008-07-30
PE20071139A1 (es) 2007-11-16
CA2631811A1 (en) 2007-06-28
JP2013177406A (ja) 2013-09-09
TWI469788B (zh) 2015-01-21
US20250082718A1 (en) 2025-03-13
BR122019027412B8 (pt) 2021-07-27
IL191842A0 (en) 2008-12-29
IN2015DN03936A (no) 2015-10-02
BRPI0620063B8 (pt) 2021-05-25
RU2464972C2 (ru) 2012-10-27
EP2359809B1 (en) 2019-08-14
KR20130024988A (ko) 2013-03-08
PL1968549T3 (pl) 2014-10-31
AR058591A1 (es) 2008-02-13
JP2015044823A (ja) 2015-03-12
BRPI0620063A2 (pt) 2011-11-01
CN103251929A (zh) 2013-08-21
BRPI0620063A8 (pt) 2018-05-02
CL2018003398A1 (es) 2019-04-26
JP6178772B2 (ja) 2017-08-09
WO2007071395A1 (en) 2007-06-28
US20200206306A1 (en) 2020-07-02
KR101458728B1 (ko) 2014-11-05
KR101245919B1 (ko) 2013-03-20
PL2359809T3 (pl) 2020-01-31
KR20130024987A (ko) 2013-03-08
JP2016216467A (ja) 2016-12-22
ES2492641T3 (es) 2014-09-10
ES2755032T3 (es) 2020-04-21
KR20130024986A (ko) 2013-03-08
TW200803921A (en) 2008-01-16
EP3603623A1 (en) 2020-02-05
PT2359809T (pt) 2019-11-04
US20090004283A1 (en) 2009-01-01
CA2631811C (en) 2017-06-20
KR20080078000A (ko) 2008-08-26
EP1968549A1 (en) 2008-09-17
TW201424747A (zh) 2014-07-01
BR122019027412B1 (pt) 2020-12-01
US20150037420A1 (en) 2015-02-05
EP1968549B1 (en) 2014-05-14
BRPI0620063B1 (pt) 2020-09-08
MA30064B1 (fr) 2008-12-01
JP6239851B2 (ja) 2017-11-29
JP2009520727A (ja) 2009-05-28
US20220296675A1 (en) 2022-09-22
RU2008129626A (ru) 2010-01-27
PT1968549E (pt) 2014-08-29
AU2006328950A1 (en) 2007-06-28
TWI468172B (zh) 2015-01-11
US20180140662A1 (en) 2018-05-24
KR20140133968A (ko) 2014-11-20
US20160120935A1 (en) 2016-05-05
AU2006328950B2 (en) 2010-07-29
EP2359809A1 (en) 2011-08-24

Similar Documents

Publication Publication Date Title
NO20082988L (no) Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer
ES2525410T3 (es) Composiciones y métodos para el tratamiento de enfermedades hiperproliferativas dérmicas
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
HRP20040996B1 (hr) Tablete visokog sadržaja lijeka
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
DK0991407T4 (da) Stabilisering af syresensitive benzimidazoler med amino/cyclodextrin-kombinationer
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
EP2246051A4 (en) METHOD FOR PRODUCING A RASCH IN THE MOUTH-DISKING TABLET WITH IMIDAFENACIN AS AN ACTIVE SUBSTANCE
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
ATE541562T1 (de) Ibuprofen-suspension
EP2077111A4 (en) ANTIDEPRESSANT
ATE347358T1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
DK1719503T3 (da) Anvendelse af stivelse med fraspaltede sidekæder i ekstrudering/sfæronisering af farmaceutiske pellets
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
DE602005027231D1 (de) Cylglycerolen und therapeutischen verwendungen derselben
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
UY27920A1 (es) Combinaciones de epinastina, pseudoefedrina y metilefedrina como nuevas formulaciones farmaceuticas
NO20064196L (no) Utvortes preparat for behandling av smertefulle hudskader
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application